ArticleVirchows Archiv : an international journal of pathology2006
Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.
Article in Virchows Archiv : an international journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- Reduced p63 expression is linked to unfavourable prognosis in muscle-invasive urothelial carcinoma of the bladder.BJUI compass · 2024Article
- Prognostic Value of P63 Expression in Muscle-Invasive Bladder Cancer and Association with Molecular Subtypes-Preliminary Report.Current issues in molecular biology · 2024Article
- Article
- An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.Advances in anatomic pathology · 2020Review
- Biological and Clinical Significance of GATA3 Detected from TCGA Database and FFPE Sample in Bladder Cancer Patients.OncoTargets and therapy · 2020Article
- Prognostic Role of Epithelial-Mesenchymal Transition Markers "E-Cadherin, β-Catenin, ZEB1, ZEB2 and p63" in Bladder Carcinoma.World journal of oncology · 2019Article
- Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.Pathology oncology research : POR · 2018Article
- Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.Journal of pathology and translational medicine · 2016Article
- Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67.Medical journal of the Islamic Republic of Iran · 2016Article
- Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Biomarkers for bladder cancer management: present and future.American journal of clinical and experimental urology · 2014Review
- HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.Virchows Archiv : an international journal of pathology · 2013Article
- Caspase-1 is a novel target of p63 in tumor suppression.Cell death & disease · 2013Article
- The expression of p63 in bladder cancer vs. chronic bilharzial bladder.Arab journal of urology · 2013Article
- p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis.Nature reviews. Cancer · 2013Review
- Spindle cell carcinoma progressed from transitional cell carcinoma of the urinary bladder.International journal of clinical and experimental pathology · 2012Article
- Article
- Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.The American journal of pathology · 2011Article
- Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis.Medical oncology (Northwood, London, England) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
P63 is a member of the p53 family, which plays a role in the differentiation of urothelium and is supposed to play a role in urothelial carcinogenesis. P53 and MIB-1 are recognised in many studies as predictive markers of progression, but few studies in the literature have examined p63. The aims of our study were to explore the expression of p63 in bladder carcinomas and to compare this expression to p53 and MIB-1, as well as to stage and grade. Tissue microarrays were performed on 158 urothelial carcinomas (56 pTa, 45 pT1 and 57>or=pT2). Immunohistochemical studies were performed with p63, p53 and MIB-1 antibodies. In our study we observed that p63 immunostaining is present in all cell layers in papillary urothelial neoplasm of low malignant potential (PUNLMP), but partially lost in non-invasive papillary urothelial carcinoma low grade (NILGC) and in pT1/>or=pT2 bladder cancers. P53 and MIB-1 displayed lower expression in PUNLMP/NILGC vs non-invasive papillary urothelial carcinoma high grade (NIHGC)/pT1, but there was no correlation between the expression of p63, p53 and MIB-1. Our study demonstrates that p63 expression distinguishes between PUNLMP/NILGC and NIHGC/pT1 (p=4.10(5)). A statistical difference disserving pTa and pT1/>or=pT2 with a statistical significance (p<10(-6)) could also be observed. P63 should be considered as an additional biomarker that might help pathologists to classify their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.